The Motley Fool Discussion Boards

Previous Page

International Investing / Australia (All-Ordinaries)


Subject:  Rule Breaker Date:  4/2/2002  7:49 PM
Author:  jono202 Number:  4040 of 6186

Now is time for TMF to learn from these mistakes & clean up the bad side of their methods IMO.They & I'm not suggesting it has to be TA based, need to sort out the sell side.This is how portfolio's get bent one stock can either make your port's up look great & one stock can just as easily be a killer. Whether this stock ever trades at $276 again is not yet known, but it cann't ever be disputed that it did.

To me it's a great example that we all should take note of.
Like the Gambler,
You gotta know when to hold em,
know when to fold em,
know when to walk away,
& know when to run,
You can't avoid risk after all no risk no gain, but you gotta try & put the odds in your favour.You can only judge a investment on a reward V's loss basis if you calculate possible loss(the amount under your buy in you cut your losses at),against you projected fair value(FA) /or TA price targets(reward).Thats the failure with these methods IMO, risk is not factored in , all the work go's into the stock's selection.

It's the amount of money we left on the table when we bought Celera Genomics (NYSE: CRA) on Dec. 17, 1999 for a split-adjusted $39.75 a share, rode it all the way to Feb. 25, 2000's intraday high of $276, and then all the way down, to yesterday's $20.22 close. Powered in part by Celera's astonishing trajectory, the Rule Breaker Portfolio's value came close to $1 million in Feb. 2000 -- its highest value to date. At yesterday's close, it was worth $347,281


Copyright 1996-2022 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us